195th ENMC International Workshop: Newborn screening for Duchenne muscular dystrophy 14-16th December, 2012, Naarden, The Netherlands

Neuromuscular Disorders

Volumn 23, Issue 8, 2013, Pages 682-689

  Ellis, Juliet A ^a,b   Vroom, Elizabeth ^c   Muntoni, Francesco ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Duchenne Parent Project   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CREATINE KINASE MM; DYSTROPHIN; GLUCOCORTICOID;

ARTICLE; BECKER MUSCULAR DYSTROPHY; CARDIOMYOPATHY; CLINICAL FEATURE; DISEASE ASSOCIATION; DUCHENNE MUSCULAR DYSTROPHY; DUCHENNE MUSCULAR DYSTROPHY GENE; ENZYME ASSAY; FAILURE TO THRIVE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEEDING DISORDER; FRAMESHIFT MUTATION; GENE; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; INFORMATION DISSEMINATION; MUTATIONAL ANALYSIS; NETHERLANDS; NEWBORN SCREENING; PHYSIOTHERAPY; PRIORITY JOURNAL; RARE DISEASE; RESPIRATORY FAILURE; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

CONGRESSES AS TOPIC; HUMANS; INFANT, NEWBORN; MUSCULAR DYSTROPHY, DUCHENNE; NETHERLANDS;

EID: 84880947740     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.05.008     Document Type: Article

References (45)

1. Ommen G.J.B., Scheuerbrandt G. Workshop report, neonatal screening for muscular dystrophy. Consensus recommendation of the 14th workshop sponsored by the European Neuromuscular Center (ENMC). Neuromuscul Disord 1993, 3:231-239.
2. Emery A.E.H., Muntoni F. Duchenne muscular dystrophy 2003, Oxford University Press.
3. Simonds A.K., Muntoni F., Heather S., Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax 1998, 53:949-952.
4. Eagle M., Baudouin S.V., Chandler C., Giddings D.R., Bullock R., Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002, 12:926-929.
5. Eagle M., Bourke J., Bullock R., et al. Managing Duchenne muscular dystrophy- the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007, 17:470-475.
6. Bushby K., Finkel R., Birnkrant D.J. For the DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management and part 2: implementation of multidisciplinary care. Lancet Neurol 2010, 9:77-93.
7. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010, 9:177-189.
8. Mohamed K., Appleton R., Nicolaides P. Delayed diagnosis of DMD. Eur J Paediatric Neurol 2000, 4:219-223.
9. Marshall P.D., Galasko C.S. No improvement in delay in diagnosis of DMD. Lancet 1995, 345:590-591.
10. Ciafaloni E., Fox D.J., Pandys P., et al. Delayed diagnosis in DMD: data from the MD surveillance, tracking and research network (MD STARnet). J Pediatr 2009, 155:380-385.
11. Ricotti V., Ridout D.A., Scott E., et al. On behalf of the NorthStar Clinical Network. Long-term benefits and adverse effects of intermittent versus daily glucorticoids in boys with DMD. J Neurol Neurosurg Psychiatry 2013, 84:698-705.
12. Emery A.E. Population frequencies of inherited neuromuscular diseases - a world survey. Neuromuscul Disord 1991, 1:19-29.
13. Mendell J.R., Shilling C., Leslie N.D., et al. Evidence-based path to newborn screening for DMD. Ann Neurol 2012, 71:304-313.
14. Mendell J.R., Lloyd-Puryear M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve 2013, 10.1002/mus.23810.
15. Wilson J.M.G., Jungner F. Principles and practice of screening for disease. Public Health Pap 1968, 34:163.
16. Andermann A., Blancquaert I., Beauchamp S., Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40years. Bull WHO 2008, 86:317-319.
17. Andermann A., Blancquaert I., Beauchamp S., Costea I. Guiding policy decisions for genetic screening: developing a systematic and transparent approach. Pub Health Genomics 2011, 14:9-16.
18. Zellweger H., Antonik A. Newborn screening for Duchenne muscular dystrophy. Pediatrics 1975, 55:30-34.
19. Heydemann A., Doherty K.R., McNally E.M. Genetic modifiers of muscular dystrophy: implications for therapy. Biochim Biophys Acta 2007, 1772:216-228.
20. Moat S.J., Bradley D.M., Salmon R., Clarke A., Hartley L. Newborn screening for Duchenne muscular dystrophy: 21years experience in Wales (UK). Eur J Hum Gens 2013, 10.1038/ejhg.2012.301.
21. Greenberg C.R., Rohringer M., Jacobs H.K., et al. Gene studies in newborn males with Duchenne muscular dystrphy detected by neonatal screening. Lancet 1988, 2:425-427.
22. Hildes E., Jacobs H.K., Cameron A., et al. Impact of genetic counselling after neonatal screening for Duchenne muscular dystrophy. J Med Genet 1993, 30:670-676.
23. Heldermann-van den Enden A.T., Madan K., Breuning M.H., van der Hout A.H., Bakker E., de Die-Smulders C.E.M., et al. An urgent need for a change in policy revealed by a study on prenatal testing for DMD. Eur J Hum Gens 2013, 21:21-26.
24. Scheuerbrandt G., Lundin A., Lövgren T., Mortier W. Screening for Duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program. Muscle Nerve 1986, 9:11-23.
25. Smith R.A., Sibert J.R., Harper P.S. Early development of boys with Duchenne muscular dystrophy. Dev Med Child Neurol 1990, 32:519-527.
26. Pane M., Scalise R., Berardinelli A., et al. Early developmental assessment in DMD. Neuromuscul Disord 2013, 23:451-455.
27. Eilers R., Kleinveld J.H., Vroom E., Westerman M.J., Plass A.M.C. Desirability of early identification of Duchenne muscular dystrophy (DMD): parent's experiences of the period prior to diagnosis. Eur J Hum Genet 2010, 18:374-375.
28. Eilers R., Veldman-Ariesen M.J., Haenen A., van Benthem B.H. Prevalence and determinants associated with healthcare-associated infections in long-term care facilities (HALT) in the Netherlands, May to June 2010. Euro Surveill 2012, 17(34). pii:20252.
29. Merlini L., Gennari M., Malaspina E., et al. Early corticosteroid treatment in 4 DMD patients: 14year follow up. Muscle Nerve 2012, 45:796-802.
30. Finkel R.S. Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 2010, 25:1158-1164.
31. Kinali M., Arechavala-Gomeza V., Feng L., et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in DMD: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009, 8:918-928.
32. Goemans N.M., Tulinius M., van den Akker J.T., et al. Systemic administration of PRO051 in Duchenne muscular dystrophy. N Engl J Med 2011, 364:1513-1522.
33. Muntoni F. On behalf of the TREAT-NMD network. The development of antisense oligonucleotide therapies for DMD: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul Disord 2010, 20:355-362.
34. Bushby K., Connor E. Clinical outcome measures for trials in DMD: report from international working group meetings. J Clin Invest 2011, 1:1217-1235.
35. Plass A.M., van El C.G., Pieters T., Cornel M.C. Treatable and untreatable diseases in the neonatal-screening program: the opinion of Dutch prospective parents. Pediatrics 2010, 125:e99-e106.
36. Bekker H., Modell M., Denniss G., Bobrow M., Marteau T. Uptake of cystic fibrosis testing in primary care: supply push or demand pull?. Brit Med J 1993, 306:1584-1586.
37. Parsons E.P., Moore C., Israel J., Hood K., Clarke A.J., Bradley D.M. Emphasizing parental choice on newborn screening. Br J Midwifery 2005, 13:165-169.
38. Parsons E.P., King J.T., Israel J.A., Bradley D.M. Mothers' accounts of screening newborn babies in Wales (UK). Midwifery 2007, 23:59-65.
39. Campbell E., Ross L.F. Parental attitudes regarding newborn screening for PKU and DMD. Am J Med Genet Part A 2003, 120A:209-214.
40. Parsons E.P., Clarke A.J., Hood K., Lycett E., Bradley D.M. Newborn screening for DMD: a psychococial study. Arch Dis Child Fetal Neonatal Ed 2002, 86:F91-F95.
41. Loeber J.G., Burgard P., Cornel M.C., et al. Newborns screening programmes in Europe; arguments and efforts regarding harmonization. Part 1 - From blood spot to screening result. J Inherit Metab Dis 2012, 35:603-611.
42. Burgard P., Rupp K., Lindner M., et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 - From screening laboratory results to treatment, follow-up and qulaity assurance. J Inherit Metab Dis 2012, 35:613-625.
43. Parsons E.P., King J.T., Israel J.A., Bradley D.M. Mother's accounts of screening newborn babies in Wales (UK). Midwifery 2007, 23:59-65.
44. Plass A.M., Baars M.J., Cornel M.C., et al. Testing the children: do non-genetic health-care providers differ in their decision to advise genetic pre-symptomatic testing on minors? A cross-sectional study in five countries in the European Union. Genet Test Mol Biomarkers 2009, 13:367-376.
45. Acharya K., Ackerman P.D., Ross L.F. Pediatricians' attitudes toward expanding newborn screening. Pediatrics 2005, 116:e476-e484.